4/23
08:05 am
anro
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Low
Report
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
4/9
11:02 am
anro
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions [Yahoo! Finance]
Low
Report
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions [Yahoo! Finance]
4/3
08:05 am
anro
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
Low
Report
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
3/25
11:50 am
anro
Alto Neuroscience, Inc. (NYSE: ANRO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $32.00 price target on the stock.
Medium
Report
Alto Neuroscience, Inc. (NYSE: ANRO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $32.00 price target on the stock.
3/21
04:05 pm
anro
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
Medium
Report
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
3/11
08:05 am
anro
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Medium
Report
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
3/7
08:00 am
anro
Alto Neuroscience to Participate in Upcoming Investor Conferences
Medium
Report
Alto Neuroscience to Participate in Upcoming Investor Conferences
2/27
08:16 am
anro
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at TD Cowen. They set an "outperform" rating on the stock.
High
Report
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at TD Cowen. They set an "outperform" rating on the stock.
2/27
08:16 am
anro
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
High
Report
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
2/27
08:00 am
anro
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
High
Report
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
2/27
07:08 am
anro
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $32.00 price target on the stock.
Medium
Report
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $32.00 price target on the stock.
2/27
07:08 am
anro
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $33.00 price target on the stock.
Medium
Report
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $33.00 price target on the stock.
2/27
07:08 am
anro
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $32.00 price target on the stock.
Medium
Report
Alto Neuroscience, Inc. (NYSE: ANRO) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $32.00 price target on the stock.
2/6
04:05 pm
anro
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Low
Report
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2/1
08:57 pm
anro
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
Medium
Report
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering